Two studies from Denmark [32, 36], using a grace period of 90 days (as was done in our main analyses), reported that approximately 20% of both GLP-1 receptor agonist users [32, 36] and SGLT2 inhibitor users [32] had discontinued treatment within 1 year of treatment initiation
Although our body can produce glutathione naturally, the amount is typically very limited
New data from a massive cohort study of 2 million patients published in Nature Medicine in January 2025, suggest that GLP-1 medications may actually reduce the risk of substance use disorders , including Cannabis Use Disorder (CUD)
With a wealth of data in support of its safety and efficacy, semaglutide stands out among the breakthrough antiobesity drugs that have emerged in response to the obesity epidemic
If anything, the most challenging time tends to be the first week or two on each new dose, when our body is adjusting to the increase
Although costly and still limited in insurance coverage, it offers unmatched weight loss potential at this time